Discovery of Novel *N*-Isoxazolylphenyltriazinones as Promising Protoporphyrinogen IX Oxidase Inhibitors

Da-Wei Wang,[#] Rui-Bo Zhang,[#] Shu-Yi Yu, Lu Liang, Ismail Ismail, Yong-Hong Li, Han Xu,

Xin Wen, and Zhen Xi*

State Key Laboratory of Elemento-Organic Chemistry, and Department of Chemical Biology,

National Pesticide Engineering Research Center, Collaborative Innovation Center of Chemical

Science and Engineering, College of Chemistry, Nankai University, Tianjin 300071, P. R. China.

*corresponding author: E-mail: zhenxi@nankai.edu.cn (Z. Xi), Tel: +86 022-23504782. Fax:

+86 022-23504782.

[#]D.-W. W. and R.-B. Z. contributed equally to this work.

Contents:

Figure S1. Superimposition of the structures 33 3D-QSAR training set compounds	S2
Figure S2. Plot of the Open3DQSAR calculated versus experimental pK _i values	S2
Figure S3. The results of HPLC analysis of 5a .	S3
Figure S4. UPLC-HRMS analysis of the leaves extracts.	S3
Table S1. Pre- and Post-emergent Herbicidal Activity of Compound 5a and Saflufenacil	S4
Table S2. Post-emergent Herbicidal Spectrum of Compound 5a and Saflufenacil	S5
Table S3. Calculated Binding Free Energies (kcal/mol) of <i>R</i> -5a and <i>S</i> -5a with NtPPO	S6
Table S4. Statistics of 3D-QSAR Model	S6
Table S5. Calculated CLogP Values of Compounds 5-9.	S7
1. General Methods	S9
2. Pre-emergence herbicidal Activity Evaluation Method.	S9
3. Binding energy calculation.	S9
4. PPO Inhibition Assay.	S11
5. Experimental Procedures for the Synthesis of compounds 5-9	S12
Representative ¹ H NMR and ¹³ C NMR Spectrum.	S37



Figure S1. Superimposition of the structures 33 3D-QSAR training set compounds.



Figure S2. Plot of the Open3DQSAR calculated versus experimental pK_i values.



Figure S3. The results of HPLC analysis of 5a. (A) Purity analysis of 5a; (B) Analysis of the reaction solution at 10 min.



Figure S4. UPLC-HRMS analysis of the leaves extracts.

aamnda	dosage	%/inhibition (pre-emergence)			%/inhibition (post-emergence)				
compus	g ai/ha	ABUJU ^a	AMATR	ECHCG	DIGSA	ABUJU ^a	AMATR	ECHCG	DIGSA
5a	150	100	100	100	100	100	100	100	100
	75	100	100	81	68	100	100	100	100
	37.5	100	100	44	65	100	100	100	100
	18.75	95	96	34	24	100	98	99	96
	9.375	31	33	30	20	96	97	83	81
saflufenacil	150	100	100	94	88	100	100	100	100
	75	100	100	79	63	100	100	100	100
	37.5	100	100	41	59	100	100	100	77
	18.75	100	100	34	19	100	100	90	50
	9.375	100	100	25	8	100	100	65	38

Table S1. Pre- and Post-emergent Herbicidal Activity of Compound 5a and Saflufenacil.

^{*a*}Abbreviations: ABUJU, *Abutilon juncea*; AMATR, *Amaranthus tricolor*; ECHCG, *Echinochloa crus-galli*; DIGSA, *Digitaria sanguinalis*.

wooda		5a (g ai/ha)			saflufenacil (g ai/ha)		
weeds		75	37.5	18.75	75	37.5	18.75
Cassia tora	CASTO	100	100	100	100	100	100
Leptochloa panicea	LEPPA	100	95	95	100	85	85
Aeschynomene indica	AESIN	100	100	100	100	100	100
Vicia gigantean	VICGI	95	85	80	95	95	90
Setaria faberii	SETFA	100	100	85	90	80	80
Sorghum halepense	SORHA	85	85	50	90	30	30
Pharbitis nil	PHANI	100	100	100	100	100	100
Xanthium sibiricum	XANSI	100	100	80	100	100	100
Bidens pilosa	BIDPI	100	90	85	100	100	100
Clinopodium chinense	CLICH	100	100	100	100	100	100
Eclipta prostrate	ECLPR	100	100	70	100	100	100
Commelina benghalensis	COMBE	100	100	100	100	100	100
Phytolacca acinosa	PHYAC	100	100	100	100	100	100
Beckmannia syzigachne	BECSY	95	85	0	90	30	0
Orychophragmus violaceus	ORYVI	90	85	80	100	100	100
Brassica juncea	BRAJU	85	80	70	100	100	100
Capsella bursa	CAPBU	95	85	80	100	100	100
Stellaria media	STEME	100	95	70	100	100	100
Veronica didyma	VERDI	100	100	100	100	100	100
Chenopodium serotinum	CHESE	100	100	100	100	100	100
Trifolium repens	TRIRE	100	100	100	100	100	100
Rumex acetosa	RUMAC	100	100	95	100	100	100
Descurainia sophia	DESSO	100	100	100	100	100	100
Polypogon fugax	POLFU	100	100	90	95	95	90
Poa annua	POAAN	100	100	95	95	90	85
Eleusine indica	ELEIN	95	90	70	70	60	60
Isodon serra	ISOSE	100	95	90	100	100	100
Boehmeria nivea	BOENI	100	100	100	100	100	100
Averaged inhibition percentage			95.4	85.2	97.3	91.6	90.0

 Table S2. Post-emergent Herbicidal Spectrum of Compound 5a and Saflufenacil.

 $\Delta E_{\rm MM}$ $-T\Delta S$ compds $\Delta E_{\rm ele}$ $\Delta E_{\rm VDW}$ $\Delta G_{
m sol}$ $\Delta E_{\rm bind}$ $\Delta G_{
m bind}$ -23.09 -82.53 *R*-5a -59.44 43.97 -38.66 9.55 -29.11 -28.59 S-5a -21.26 -60.65 -81.91 43.89 -38.02 9.43

Table S3. Calculated Binding Free Energies (kcal/mol) of *R*-5a and *S*-5a with NtPPO.

Table S4. Statistics of 3D-QSAR Model.

n (training set)	n (test set)	optimal PCs	r ²	q^2	$r^2_{\rm pred}$	SDEC ^a	SDEP ^b
33	9	5	0.93	0.74	0.88	0.18	0.20

^{*a*}SDEC: standard deviation of error of calculation, ^{*b*}SDEP: standard deviation of error of prediction.

compds	Х	\mathbb{R}^1	R ²	R ³	CLogP ^a
5a	F	CH ₃	CO ₂ CH ₂ CH ₃	CH ₃	3.78
5 a1	F	CH ₃	$CO_2CH_2CH_3$	CH ₂ CH ₃	4.84
5a2	F	CH_3	CO ₂ CH ₂ CH ₃	CH ₂ CH ₂ CH ₃	5.90
5a3	F	Н	CO ₂ CH ₂ CH ₃	CH ₃	3.26
5a4	F	CH_3	CH ₂ CH ₃	CH ₃	3.98
5a5	F	CH_3	CH ₂ OCOCH ₃	CH ₃	3.023
5b	F	CH_3	CO_2H	CH ₃	2.78
5c	F	CH_3	CO_2CH_3	CH ₃	3.25
5d	F	CH_3	$CO_2CH_2CH_2CH_3$	CH ₃	4.31
5e	F	CH_3	CO ₂ CH ₂ CH ₂ CH ₃ CH ₃	CH ₃	4.84
5 f	F	CH_3	$CO_2CH(CH_3)_2$	CH ₃	4.09
5g	F	CH_3	$CO_2CH_2CH_2F$	CH ₃	3.50
5h	F	CH_3	$CO_2CH_2CHF_2$	CH ₃	3.83
5i	F	CH_3	CO ₂ CH ₂ CH ₂ CH ₂ F	CH ₃	3.73
5j	F	CH_3	$CO_2CH_2CO_2C_2H_5$	CH ₃	3.67
5k	F	CH_3	$CO_2CH(CH_3)CO_2C_2H_5$	CH ₃	3.98
51	F	CH_3	$CO_2C(CH_3)_2CO_2C_2H_5$	CH ₃	4.29
5m	F	CH_3	CO ₂ CHFCO ₂ C ₂ H ₅	CH ₃	3.74
5n	F	CH_3	$CO_2CF_2CO_2C_2H_5$	CH ₃	5.11
50	F	CH_3	$CO_2CH_2C_6H_5$	CH ₃	4.91
5p	F	CH_3	$CO_2CH_2C_6H_4(4-CF_3)$	CH ₃	5.80
5q	F	CH_3	$CO_2CH_2C_6H_4(4-F)$	CH ₃	5.06
5r	F	CH_3	$CO_2CH_2C_6H_4(4-CH_3)$	CH ₃	5.41
6a	Cl	CH_3	$CO_2CH_2CH_3$	CH ₃	4.35
6b	Cl	CH_3	$\rm CO_2 H$	CH ₃	3.35
6c	Cl	CH_3	CO_2CH_3	CH ₃	3.82
6d	Cl	CH_3	$CO_2CH_2CH_2CH_3$	CH ₃	4.88
6e	Cl	CH_3	$CO_2CH_2CH_2CH_2CH_3$	CH ₃	5.41
7a	Br	CH ₃	$CO_2CH_2CH_3$	CH ₃	4.50
7b	Br	CH ₃	$\rm CO_2 H$	CH ₃	3.50
7c	Br	CH ₃	CO ₂ CH ₃	CH ₃	3.97
7d	Br	CH ₃	$CO_2CH_2CH_2CH_3$	CH ₃	5.03
7e	Br	CH ₃	$CO_2CH_2CH_2CH_2CH_3$	CH ₃	5.56
8a	Н	CH ₃	$CO_2CH_2CH_3$	CH ₃	3.59
8b	Н	CH ₃	CO ₂ H	CH ₃	2.59
8c	Н	CH ₃	CO_2CH_3	CH ₃	3.06
8d	Н	CH ₃	$CO_2CH_2CH_2CH_3$	CH ₃	4.12
8e	Н	CH ₃	$CO_2CH_2CH_2CH_2CH_3$	CH ₃	4.65
9a	F	CH ₃	CONHCH ₃	CH ₃	2.68
9b	F	CH ₃	CONHCH ₂ CH ₃	CH ₃	3.21
9c	F	CH ₃	CONHCH ₂ CH ₂ CH ₃	CH ₃	3.74
9d	F	CH ₃	$CONHCH(CH_3)_2$	CH ₃	3.52
9e	F	CH ₃	CONHCH ₂ CH ₂ CH ₂ CH ₃	CH ₃	4.27

 Table S5. Calculated CLogP Values of Compounds 5-9.

9f	F	CH_3	CONHCH ₂ CH(CH ₃) ₂	CH ₃	4.14
9g	F	CH_3	CONHC(CH ₃) ₃	CH ₃	3.92
9h	F	CH_3	CONHCH ₂ C ₆ H ₅	CH ₃	4.46
9i	F	CH_3	CONHSO ₂ N(CH ₃)CH(CH ₃) ₂	CH ₃	4.00

^aCLogP values were predicted by ChemBioDraw Ultra 14.0.

1. General Methods

All chemical reagents and solvents were commercially available (Innochem, Science & Technology Co., Ltd. Beijing, China or J&K Scientific Ltd. Beijing, China) and used directly in the experiment without further purification. NMR spectra were recorded on a VARIAN Mercury-Plus 400 spectrometer (Bruker Corp., Switzerland) in CDCl₃ or DMSO- d_6 with tetramethylsilane (TMS) as the internal reference. High-resolution mass spectra (HRMS) were obtained on an FT-ICR mass spectrometer (Ionspec, 7.0 T). Melting points were taken on a Buchi B-565 melting point apparatus and are uncorrected.

2. Pre-emergence herbicidal Activity Evaluation Method.

Two representative broadleaf weeds: *A. juncea* and *A. tricolor*; and two representative monocotyledon weeds: *E. crusgalli* and *D. sanguinalis* were tested. Saflufenacil was used as a positive control. Before testing, compounds were dissolved in DMF and formulated with Tween-80 as emulsification reagent to a concentration of 100 g/L. Clay soil, pH 6.5, CEC 12.1 mol/kg, 37.3% clay particles, and 1.6% organic matter was used in the experiment. The active ingredient (g ai/ha) was calculated by the total amount of active ingredients in the formulation divided by the surface area of the pot. In the experiment, plastic pots with a diameter of 9 centimeters were filled with clay soil to a depth of 8 centimeters. About 20 of tested weeds seeds were sown in the pots at the depth of 1 to 3 centimeter and grown at 15 to 30 °C in the greenhouse. After sowing the seeds in the plastic pots, they were directly treated with **5a** and saflufenacil at 9.375-150 g ai/ha, with DMF+Tween-80-treated groups as solvent control. During the control group and testing groups above the tested soil was measured, and the inhibition rates were calculated by comparing to control values, with three replicates per treatment, the results are shown in Table S1.

3. Binding energy calculation.

After molecular docking, the best binding modes of *R*-5a and *S*-5a were used for the Binding energy calculation; the results are shown in Table S2. The binding free energy for each of the minimized inhibitor-protein was estimated using the molecular mechanics-Possion-Boltzmann surface area (MM-PBSA) method.¹ The binding free energy with receptor, ΔG_{bind} , was calculated according to the eq 1.

 $\Delta G_{\text{bind}} = G_{\text{complex}} - G_{\text{receptor}} - G_{\text{ligand}} \quad (1)$

Where, G_{complex} is the free energy of receptor-ligand complex, G_{receptor} is the free energy of unbound receptor, G_{ligand} is the free energy of ligand.

The binding free energy ΔG_{bind} was calculate according to three items: MM gas-phase binding energy (ΔE_{MM}), solvation free energy (ΔG_{sol}) and entropic contribution (-T ΔS), see eq2. The binding energy (ΔE_{bind}) is the sum of gas-phase binding energy (ΔE_{MM}) and solvation free energy (ΔG_{sol}), see eq3

$$\Delta G_{\text{bind}} = \Delta E_{\text{bind}} - T\Delta S \qquad (2)$$
$$\Delta E_{\text{bind}} = \Delta E M M + \Delta G_{\text{sol}} \qquad (3)$$

 $\Delta E_{\rm MM}$ was calculated by eq. 4, where, $\Delta E_{\rm ele}$ and $\Delta E_{\rm vdw}$ are electrostatic and van der Waals (vdw), respectively. $\Delta G_{\rm sol}$ was calculated by eq. 5, where, $\Delta G_{\rm PB}$ is the electrostatic contribution to the solvation free energy and $\Delta G_{\rm np}$ is nonelectrostatic contribution to the solvation free energy.

$$\Delta E_{\rm MM} = \Delta E_{\rm ele} + \Delta E_{\rm vdw} \qquad (4)$$
$$\Delta G_{\rm sol} = \Delta G_{\rm PB} + \Delta G_{\rm np} \qquad (5)$$

The electrostatic contribution to the solvation free energy (ΔG_{PB}) was calculated by Poisson-Boltzmann (PB) method. ΔG_{np} is the nonelectrostatic contribution to the solvation free energy determined as a function of the solvent accessible surface area (SASA).

The entropic contribution to the binding free energy consists of two parts: ΔS_{sol} and ΔS_{conf} , see eq. 6. ΔS_{sol} is the solvation entropy change and ΔS_{conf} is the conformational entropy change.

$$\Delta S = \Delta \underline{S}_{sol} + \Delta S_{conf} \qquad (6)$$

The conformational entropy change is related to the change of the number of rotatable bonds during the binding process, and the solvation entropy is related to the tendency of water molecules to minimize their contacts with hydrophobic groups in protein.

¹ Huang, Z. Y.; Yang, J. F.; Song, K.; Chen, Q.; Zhou, S. L.; Hao, G. F.; Yang, G. F., One-pot approach to *N*-quinolyl 3'/4'-biaryl carboxamides by microwave-assisted suzuki-miyaura coupling and *N*-boc deprotection. *J. Org. Chem.* **2016**, *81*, 9647-9657.

4. PPO Inhibition Assay.

The expression and purification of *Nicotiana tabacum* mitochondrial PPO2 (*Nt*PPO) were performed as described previously²⁻³ The enzyme substrate protoporphyrinogen IX was synthesized by reduction of protoporphyrin IX with freshly prepared sodium amalgam. Due to the chemical nature of protoporphyrin IX, it has a maximum excitation at 410 nm and a maximum emission of 630 nm. In the kinetic inhibition assays, we used a fluorescence detector to monitor the formation of the protoporphyrin IX by setting the emission wavelengths to 631 nm and excitation wavelengths to 410. Inhibitors were dissolved in dimethyl sulfoxide (DMSO) as a stock solution and diluted to the different concentration ranges from 0.05 μ M to 50 mM just before using. The total volume of reaction solution was 200 μ L, which consists of 0-40 μ g PPO, 5 μ M FAD, 5 mM DTT, 1 mM EDTA, 0.2 M imidazole, 0.1 M potassium phosphate buffer (pH 7.4), and 0.03% Tween 80 (v/v). To initiate the PPO reaction, 0-6.5 μ M protoporphyrinogen IX was added to the assay solution.

The half maximal inhibitory concentration (IC₅₀) value of inhibitors was calculated by fitting v versus [*I*] data to a single binding site model (eq 1). The kinetic parameters were calculated by Sigma Plot software 10.0 (SPSS, Chicago, IL).

$$y = \min + \frac{\max - \min}{1 + 10^{\log C_{50} - x}}$$
 (1)

in this equation, y is the percentage of the maximal rate, min and max being the y values at which the curve levels off, x is the logarithm of inhibitor concentration. The inhibition constant of the enzymatic reaction (K_i) was calculated by using the following relationship among IC₅₀, K_i , and K_m at any saturated substrate concentration (eq 2).

$$K_{\rm i} = \frac{\rm IC_{50}}{S/K_{\rm m} + 1}$$
 (2)

Wang, D. W.; Li, Q.; Wen, K.; Ismail, I.; Liu, D. D.; Niu, C. W.; Wen, X.; Yang, G. F.; Xi, Z., Synthesis and herbicidal activity of pyrido[2,3-d]pyrimidine-2,4-dione-benzoxazinone hybrids as protoporphyrinogen oxidase inhibitors. J. Agric. Food Chem. 2017, 65, 5278-5286.

Hao, G. F.; Zuo, Y.; Yang, S. G.; Chen, Q.; Zhang, Y.; Yin, C. Y.; Niu, C. W.; Xi, Z.; Yang, G. F., Computational discovery of potent and bioselective protoporphyrinogen IX oxidase inhibitor via fragment deconstruction analysis. *J. Agric. Food Chem.* 2017, 65, 5581-5588.

^{3.} Zuo, Y.; Wu, Q.; Su, S. W.; Niu, C. W.; Xi, Z.; Yang, G. F., Synthesis, herbicidal activity, and QSAR of novel *N*-benzothiazolyl-pyrimidine-2,4-diones as protoporphyrinogen oxidase inhibitors. *J. Agric. Food Chem.* **2016**, *64*, 552-562.

5. Experimental Procedures for the Synthesis of compounds 5-9.

5.1 Synthesis of compounds 2.



2-chloro-4-substituted-5-nitrobenzaldehyde **1** (206 mmol) was dissolved in ethanol (200 mL) and cooled to 0 °C, and then a solution of hydroxylamine hydrochloride (250 mmol) in H₂O (20 mL) was added dropwise in 15 min with stirring. Then the reaction solution was moved to room temperature and stirred for another 2 h. After completing the reaction by TLC detection, the reaction solution was poured to H₂O (1000 mL) and stirred vigorously for 30 min. The resulting solid was filtered and washed with H₂O (300 mL), dried in vacuum to afford the corresponding compounds **2**.

2-chloro-4-fluoro-5-nitrobenzaldehyde oxime (2a). White solid; m.p.: 89.6-90.9 °C; 91% yield; ¹H NMR (400 MHz, DMSO- d_6) δ 12.08 (s, 1H), 8.45 (d, J = 8.0 Hz, 1H), 8.34 (s, 1H), 8.01 (d, J = 11.2 Hz, 1H).

2,4-dichloro-5-nitrobenzaldehyde oxime (2b). White solid; m.p.: 108.0-109.8 °C; 96% yield; ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.19 (s, 1H), 8.40 (s, 1H), 8.34 (s, 1H), 8.12 (s, 1H).

4-bromo-2-chloro-5-nitrobenzaldehyde oxime (2c). White solid; m.p.: 118.7-120.4°C; 95% yield; ¹H NMR (400 MHz, DMSO- d_6) δ 12.18 (s, 1H), 8.35 (s, 1H), 8.33 (s, 1H), 8.22 (s, 1H).

2-chloro-5-nitrobenzaldehyde oxime (2d). Yellow solid; m.p.: 149.2-151.0 °C; 95% yield; ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.14 (s, 1H), 8.52 (d, *J* = 2.8 Hz, 1H), 8.40 (s, 1H), 8.22 (dd, *J* = 8.8, 2.8 Hz, 1H), 7.83 (d, *J* = 8.8 Hz, 1H).

5.2 Synthesis of compounds 3.



Compounds 2 (2.3 mmol) was dissolved in DMF (10 mL), and the solution was heated to 35 °C, and then *N*-chlorosuccinimide (NCS, 2.76 mmol) was added to solution in three portions with stirring. After stirring for another 1 h, the reaction was cooled to room temperature, CH_2Cl_2 (30 mL) and 1 M HCl solution (30 mL) were added to the solution. The organic layer was separated, and the water layer was extracted with another 20 mL of CH_2Cl_2 . The combined organic layer was washed with H_2O (20 mL) and saturated NaCl solution (20 mL), dried with anhydrous Na₂SO₄, filtered to afford the intermediates solution, which can be used directly in the next step without further purification. The filtrate was cooled to 0 °C, and then a solution of $CH_2=CR^1R^2$ (3.0 mmol) and Et_3N (3.0 mmol) in CH_2Cl_2 (10 mL) was added in 10 min. After stirring for another one hour, 1 M HCl solution (30 mL) was added to the reaction solution and stirred vigorously for 10 min. The organic layer was separated and washed with saturated NaCl solution (20 mL), dried over anhydrous Na₂SO₄ and concentrated in vacuo, purified by flash chromatography to give compounds **3**.



ethyl 3-(2-chloro-4-fluoro-5-nitrophenyl)-5-methyl-4,5-dihydroisoxazole-5-carboxylate (3a). Yellow oil; 98% yield; ¹H NMR (400 MHz, CDCl₃) δ 8.46 (d, J = 8.0 Hz, 1H), 7.45 (d, J = 10.0 Hz, 1H), 4.30 (qd, J = 7.2, 1.2 Hz, 2H), 4.02 (d, J = 17.6 Hz, 1H), 3.40 (d, J = 17.6 Hz, 1H), 1.77 (s, 3H), 1.36 (t, J = 7.2 Hz, 3H).



ethyl 3-(2-chloro-4-fluoro-5-nitrophenyl)-4,5-dihydroisoxazole-5-carboxylate (3a1). Yellow oil; 89% yield; ¹H NMR (400 MHz, CDCl₃) δ 8.46 (d, J = 7.6 Hz, 1H), 7.47 (d, J = 10.0 Hz, 1H),

5.36 – 5.08 (m, 1H), 4.31 (q, J = 7.2 Hz, 2H), 3.90 – 3.71 (m, 2H), 1.36 (t, J = 7.2 Hz, 3H).



3-(2-chloro-4-fluoro-5-nitrophenyl)-5-ethyl-5-methyl-4,5-dihydroisoxazole (3a2). Yellow oil; 77% yield; ¹H NMR (400 MHz, CDCl₃) δ 8.41 (d, *J* = 8.0 Hz, 1H), 7.42 (d, *J* = 10.0 Hz, 1H), 3.29 (d, *J* = 17.2 Hz, 1H), 3.16 (d, *J* = 17.2 Hz, 1H), 1.79 (q, *J* = 7.6 Hz, 2H), 1.47 (s, 3H), 1.01 (t, *J* = 7.6 Hz, 3H).



(3-(2-chloro-4-fluoro-5-nitrophenyl)-5-methyl-4,5-dihydroisoxazol-5-yl)methylacetate(3a3). Yellow oil; 20% yield; ¹H NMR (400 MHz, CDCl₃) δ 8.42 (d, J = 7.6 Hz, 1H), 7.43 (d, J =10.0 Hz, 1H), 4.25 (d, J = 12.0 Hz, 1H), 4.15 (d, J = 11.6 Hz, 1H), 3.48 (d, J = 17.2 Hz, 1H), 3.24(d, J = 17.2 Hz, 1H), 2.11 (s, 3H), 1.55 (s, 3H).



ethyl 3-(2,4-dichloro-5-nitrophenyl)-5-methyl-4,5-dihydroisoxazole-5-carboxylate (3b). Yellow solid; m.p.: 75.7-76.5°C; 99% yield; ¹H NMR (400 MHz, CDCl₃) δ 8.30 (s, 1H), 7.66 (s, 1H), 4.28 (d, J = 7.2 Hz, 2H), 4.01 (d, J = 17.6 Hz, 1H), 3.39 (d, J = 17.6 Hz, 1H), 1.74 (s, 3H), 1.34 (t, J = 7.2 Hz, 3H).



ethyl 3-(4-bromo-2-chloro-5-nitrophenyl)-5-methyl-4,5-dihydroisoxazole-5-carboxylate (3c).

Yellow solid; m.p.: 79.6-81.6°C; 97% yield; ¹H NMR (400 MHz, CDCl₃) δ 8.26 (s, 1H), 7.85 (s,

1H), 4.28 (q, *J* = 7.2 Hz, 2H), 4.02 (d, *J* = 17.6 Hz, 1H), 3.39 (d, *J* = 17.2 Hz, 1H), 1.74 (s, 3H), 1.33 (d, *J* = 7.2 Hz, 3H).



ethyl 3-(2-chloro-5-nitrophenyl)-5-methyl-4,5-dihydroisoxazole-5-carboxylate (3d). Yellow solid; m.p.: 55.7-57.0 °C; 95% yield; ¹H NMR (400 MHz, CDCl₃) δ 8.53 (d, *J* = 2.4 Hz, 1H), 8.18 (dd, *J* = 8.8, 2.8 Hz, 1H), 7.60 (d, *J* = 8.8 Hz, 1H), 4.27 (tt, *J* = 8.0, 6.8 Hz, 2H), 4.00 (d, *J* = 17.2 Hz, 1H), 3.40 (d, *J* = 17.2 Hz, 1H), 1.73 (s, 3H), 1.32 (t, *J* = 7.2 Hz, 3H).

5.3 Synthesis of compounds 4.



Compounds 4 (15.1 mmol), NH₄Cl (45.3 mmol), and EtOH (90%, 60 mL) were added to a flask, and the mixture was heated to reflux. Iron powder (45.3 mmol) was added portionwise to the solution in one hour, and the reaction mixture was refluxed for another 4 h. After completing the reaction, the hot reaction mixture was filtrated through a pad of celite, and the residue was washed with ethyl acetate (50 mL). H₂O (100 mL) was added to the filtrate, and the organic layer was separated. The water layer was extracted by 50 mL of ethyl acetate, the combined organic layer washed with water (30 mL) and saturated NaCl solution (30 mL), dried over anhydrous Na₂SO₄ and concentrated by rotary evaporation to give compounds **4**.



ethyl 3-(5-amino-2-chloro-4-fluorophenyl)-5-methyl-4,5-dihydroisoxazole-5-carboxylate

(4a). Yellow solid; m.p.: 78.2-80.2.0 °C; 98% yield; ¹H NMR (400 MHz, CDCl₃) δ 8.46 (d, J = 8.0 Hz, 1H), 7.45 (d, J = 10.0 Hz, 1H), 4.30 (qd, J = 7.2, 1.2 Hz, 2H), 4.02 (d, J = 17.6 Hz, 1H), 3.40 (d, J = 17.6 Hz, 1H), 1.77 (s, 3H), 1.36 (t, J = 7.2 Hz, 3H).



ethyl 3-(5-amino-2-chloro-4-fluorophenyl)-4,5-dihydroisoxazole-5-carboxylate (4a1). Yellow oil; 35% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.17 (d, *J* = 9.2 Hz, 1H), 7.08 (d, *J* = 10.4 Hz, 1H), 5.16 (dd, *J* = 11.2, 7.2 Hz, 1H), 4.31 – 4.25 (m, 2H), 3.76 (qd, *J* = 17.6, 11.2 Hz, 2H), 1.33 (t, *J* = 7.2 Hz, 3H).



4-chloro-5-(5-ethyl-5-methyl-4,5-dihydroisoxazol-3-yl)-2-fluoroaniline (4a2). Yellow oil; 78% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.19 – 7.10 (m, 1H), 7.10 – 7.01 (m, 1H), 4.00 (s, 2H), 3.26 (d, *J* = 17.2 Hz, 1H), 3.14 (d, *J* = 17.2 Hz, 1H), 1.75 (q, *J* = 7.2 Hz, 2H), 1.43 (s, 3H), 0.99 (t, *J* = 7.6 Hz, 3H).



(3-(5-amino-2-chloro-4-fluorophenyl)-5-methyl-4,5-dihydroisoxazol-5-yl)methylacetate(4a3). Yellow oil; 89% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.08 (d, J = 9.6 Hz, 1H), 7.05 (d, J =10.4 Hz, 1H), 4.16 (d, J = 12.8 Hz, 2H), 3.44 (d, J = 17.2 Hz, 1H), 3.22 (d, J = 17.2 Hz, 1H), 2.09 (s, 3H), 1.50 (s, 3H).



ethyl 3-(5-amino-2,4-dichlorophenyl)-5-methyl-4,5-dihydroisoxazole-5-carboxylate (4b). Yellow solid; m.p.: 68.9-70.3 °C; 52% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.33 (s, 1H), 7.15 (s, 1H), 4.27 (dd, J = 14.4, 7.2 Hz, 2H), 3.94 (d, J = 17.6 Hz, 1H), 3.39 (d, J = 17.2 Hz, 1H), 1.73 (d, J = 13.6 Hz, 3H), 1.32 (t, J = 7.2 Hz, 3H).



ethyl 3-(5-amino-4-bromo-2-chlorophenyl)-5-methyl-4,5-dihydroisoxazole-5-carboxylate (4c). Yellow oil; 73% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.44 (s, 1H), 7.07 (s, 1H), 4.26 (q, J = 7.2 Hz, 2H), 4.15 (s, 2H), 3.93 (d, J = 17.2 Hz, 1H), 3.39 (d, J = 17.2 Hz, 1H), 1.71 (s, 3H), 1.32 (t, J = 7.2 Hz, 3H).



ethyl 3-(5-amino-2-chlorophenyl)-5-methyl-4,5-dihydroisoxazole-5-carboxylate (4d). Yellow oil; 84% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.17 (d, *J* = 8.4 Hz, 1H), 6.99 (d, *J* = 3.2 Hz, 1H), 6.69 (dd, *J* = 8.8, 2.8 Hz, 1H), 4.28 (q, *J* = 7.2 Hz, 2H), 3.96 (d, *J* = 17.6 Hz, 1H), 3.70 (s, 2H), 3.42 (d, *J* = 17.2 Hz, 1H), 1.73 (s, 3H), 1.34 (t, *J* = 6.8 Hz, 3H).

5.4 Synthesis of compounds 5a, 6a, 7a and 8a.



General method to synthesize of compounds **5a**, **6a**, **7a** and **8a**. $CO(OCCl_3)_2$ (8.4 mmol) and toluene (20 mL) were added to a 100 mL round bottom flask and cooled to 0 °C. A solution of **4** (16.7 mmol) and Et₃N (3.3 mmol) in toluene (20 mL) was added dropwise in 10 min, and then the mixture was heated slowly to reflux. After 10 h, the mixture was cooled to room temperature, and the solvent was removed by rotary evaporation.

Toluene (40 mL) and CS(NHR³)₂ (20.1 mmol) were added successively to the residue, and the solution was stirred at room temperature for 30 min. Then CDI (33.4 mmol) was added to the solution, and the solution was heated slowly to 85 °C for 12 h. After the reaction was completed, the reaction solution was cooled to room temperature, ethyl acetate (20 mL) and H₂O (10 mL) were added to the solution. The organic layer was separated and wash with H₂O (20 mL) and saturated NaCl solution (30 mL), dried over anhydrous Na₂SO₄ and concentrated in vacuo,

purified by flash chromatography to give 5a, 6a, 7a or 8a.



ethyl 3-(2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)-4-fluorophenyl)-5methyl-4,5-dihydroisoxazole-5-carboxylate (5a). White solid; m.p.: 68.0-69.9 °C; 59% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.74 (d, J = 7.6 Hz, 1H), 7.36 (d, J = 8.8 Hz, 1H), 4.27 (q, J = 7.2 Hz, 2H), 4.01 (d, J = 17.6 Hz, 1H), 3.77 (s, 6H), 3.39 (d, J = 17.6 Hz, 1H), 1.71 (s, 3H), 1.32 (t, J= 7.2 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.40, 171.55, 159.48, 156.90, 154.34, 146.54, 135.23, 135.13, 132.03, 126.00, 120.94, 120.80, 119.39, 119.16, 87.26, 62.18, 46.50, 36.80, 23.34, 14.09; HRMS (QFT-ESI) calcd for C₁₈H₁₈ClFN₄NaO₅S [M+Na]⁺ 479.0568, found: 479.0568.



ethyl 3-(2-chloro-5-(3,5-diethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)-4-fluorophenyl)-5methyl-4,5-dihydroisoxazole-5-carboxylate (5a1). White solid; m.p.: 58.4-59.5 °C; 60% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.76 (d, J = 7.6 Hz, 1H), 7.36 (d, J = 8.8 Hz, 1H), 4.50 (q, J = 6.8 Hz, 4H), 4.27 (q, J = 6.8 Hz, 2H), 4.01 (d, J = 17.2 Hz, 1H), 3.40 (d, J = 17.6 Hz, 1H), 1.71 (s, 3H), 1.33 (t, J = 6.8 Hz, 9H); ¹³C NMR (101 MHz, CDCl₃) δ 176.25, 171.58, 159.46, 156.88, 154.41, 145.98, 135.07, 134.97, 132.09, 125.85, 125.81, 120.81, 120.68, 119.32, 119.09, 87.24, 62.18, 46.49, 45.14, 23.34, 14.09, 11.84; HRMS (QFT-ESI) calcd for C₂₀H₂₂ClFN₄NaO₅S [M+Na]⁺ 507.0881, found: 507.0880.



ethyl 3-(2-chloro-5-(2,6-dioxo-3,5-dipropyl-4-thioxo-1,3,5-triazinan-1-yl)-4-fluorophenyl)-5methyl-4,5-dihydroisoxazole-5-carboxylate (5a2). Colorless oil; 39% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.74 (d, J = 7.6 Hz, 1H), 7.35 (d, J = 8.8 Hz, 1H), 4.40 – 4.32 (m, 4H), 4.27 (q, J = 7.2 Hz, 2H), 4.01 (d, J = 17.2 Hz, 1H), 3.40 (d, J = 17.6 Hz, 1H), 1.86 – 1.73 (m, 4H), 1.72 (s, 3H), 1.33 (t, J = 6.8 Hz, 3H), 0.96 (t, J = 7.6 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 176.66, 171.58, 159.46, 156.88, 154.41, 146.24, 135.07, 134.97, 132.08, 125.86, 125.82, 120.93, 120.79, 119.31, 119.08, 87.25, 62.18, 51.05, 46.52, 23.35, 19.86, 14.09, 11.00; HRMS (QFT-ESI) calcd for C₂₂H₂₇ClFN₄O₅S [M+H]⁺ 513.1369, found: 513.1374.



ethyl 3-(2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)-4-fluorophenyl)-4,5-dihydroisoxazole-5-carboxylate (5a3). White solid; m.p.: 73.0-74.9 °C; 64% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.74 (d, J = 7.6H z, 1H), 7.37 (d, J = 9.2 Hz, 1H), 5.19 (dd, J = 10.4, 8.0 Hz, 1H), 4.27 (q, J = 7.2 Hz, 2H), 3.79 (dd, J = 10.8, 4.4 Hz, 2H), 3.76 (s, 6H), 1.33 (t, J = 7.2 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.44, 169.66, 159.59, 157.01, 154.20, 146.55, 135.28, 135.19, 132.25, 125.50, 121.01, 120.87, 119.44, 119.21, 78.99, 62.12, 40.60, 36.80, 21.06, 14.22, 14.13; HRMS (QFT-ESI) calcd for C₁₇H₁₆ClFN₄NaO₅S [M+Na]⁺ 465.0412, found:465.0411.



3-(4-chloro-5-(5-ethyl-5-methyl-4,5-dihydroisoxazol-3-yl)-2-fluorophenyl)-1,5-dimethyl-6-th ioxo-1,3,5-triazinane-2,4-dione (5a4). White solid; m.p.: 153.7-155.4 °C; 64% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.72 (d, *J* = 7.6 Hz, 1H), 7.36 (d, *J* = 9.2 Hz, 1H), 3.78 (s, 6H), 3.32 (d, *J* = 17.2 Hz, 1H), 3.18 (d, *J* = 17.2 Hz, 1H), 1.77 (q, *J* = 7.2 Hz, 2H), 1.45 (s, 3H), 1.00 (t, *J* = 7.6 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.44, 159.13, 156.56, 154.09, 146.58, 135.03, 134.93, 131.73, 127.25, 127.20, 120.78, 120.64, 119.25, 119.02, 89.20, 65.87, 46.49, 36.80, 32.69, 25.05, 15.29; HRMS (QFT-ESI) calcd for C₁₇H₁₈CIFN₄NaO₃S [M+Na]⁺435.0670, found:435.0670.



(3-(2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)-4-fluorophenyl)-5-meth yl-4,5-dihydroisoxazol-5-yl)methyl acetate (5a5). White solid; m.p.: 75.2-77.1 °C; 64% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.74 (d, J = 8.0 Hz, 1H), 7.38 (d, J = 8.8 Hz, 1H), 4.19 (dd, J = 27.6, 11.6 Hz, 2H), 3.79 (s, 6H), 3.52 (d, J = 17.2 Hz, 1H), 3.27 (d, J = 17.2 Hz, 1H), 2.11 (s, 3H), 1.53 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.38, 170.69, 159.34, 156.76, 154.27, 146.56, 146.53, 135.09, 134.99, 131.88, 126.54, 126.50, 120.90, 120.76, 119.36, 119.13, 86.35, 67.67, 44.88, 36.80, 22.82, 20.83; HRMS (QFT-ESI) calcd for C₁₈H₁₈ClFN₄NaO₅S [M+Na]⁺ 479.0568, found:479.0567.



ethyl 3-(2,4-dichloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)phenyl)-5methyl-4,5-dihydroisoxazole-5-carboxylate (6a). White solid; m.p.: 60.2-62.2 °C; 57% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.75 (s, 1H), 7.65 (t, J = 7.6 Hz, 1H), 4.27 (q, J = 7.2 Hz, 2H), 4.01 (d, J = 17.2 Hz, 1H), 3.78 (s, 6H), 3.40 (d, J = 17.6 Hz, 1H), 1.71 (s, 3H), 1.32 (t, J = 7.2 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.53, 171.47, 154.32, 146.50, 134.90, 134.60, 132.36, 132.15, 131.73, 131.65, 130.79, 128.75, 87.39, 62.20, 46.34, 36.75, 23.35, 14.10; HRMS (QFT-ESI) calcd for C₁₈H₁₈Cl₂N₄NaO₅S [M+Na]⁺ 495.0273, found: 495.0270.



ethyl 3-(4-bromo-2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)phenyl)-5-methyl-4,5-dihydroisoxazole-5-carboxylate (7a). White solid; m.p.: 71.5-73.0 °C; 82% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.79 (s, 1H), 7.72 (s, 1H), 4.31 – 4.17 (m, 2H), 3.99 (d, *J* = 17.2 Hz, 1H), 3.76 (s, 6H), 3.37 (d, *J* = 17.6 Hz, 1H), 1.68 (s, 3H), 1.30 (t, *J* = 6.8 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.55, 171.43, 154.40, 146.45, 135.34, 135.13, 134.55, 132.57, 131.58, 131.41, 129.36, 124.78, 87.40, 62.18, 46.29, 36.74, 23.33, 14.10; HRMS (QFT-ESI) calcd for C₁₈H₁₈BrClN₄NaO₅S [M+Na]⁺ 538.9768, found: 538.9765.



ethyl 3-(2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)phenyl)-5-methyl-4,5-dihydroisoxazole-5-carboxylate (8a). White solid; m.p.: 76.4-78.4 °C; 60% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.66 (d, J = 2.8 Hz, 1H), 7.55 (d, J = 8.8 Hz, 1H), 7.26 (dd, J = 8.4, 2.4 Hz, 1H), 4.26 (q, J = 7.2 Hz, 2H), 4.01 (d, J = 17. 2 Hz, 1H), 3.76 (s, 6H), 3.41 (d, J = 17.2 Hz, 1H), 1.70 (s, 3H), 1.32 (t, J = 7.2 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.65, 171.84, 155.26, 147.45, 134.06, 132.87, 132.03, 130.76, 130.60, 130.13, 87.37, 62.33, 46.77, 36.92, 23.55, 14.29; HRMS (QFT-ESI) calcd for C₁₈H₁₉ClN₄NaO₅S [M+Na]⁺461.0662, found: 461.0661.

5.5 Synthesis of compounds 5b, 6b, 7b and 8b.



3-(2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)-4-fluorophenyl)-5-meth yl-4,5-dihydroisoxazole-5-carboxylic acid (5b). Compound **5a** (10 mmol) was dissolved in 20 mL of HOAc, then H₂O (10 mL) and H₂SO₄ (20 mL) were added to the solution with stirring, and the reaction solution was heated to 100 °C for 10 h. After completing the reaction, the reaction solution was cooled to room temperature and poured to 500 g of ice, and stirred vigorously for 30 min. The resulting solid was filtrated and washed with H₂O (50 mL), dried over in vacuum to give compound **5b**. White solid; m.p.: 120.4-122.2 °C; 80% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.74 (d, *J* = 7.6 Hz, 1H), 7.40 (d, *J* = 8.8 Hz, 1H), 4.04 (d, *J* = 17.6 Hz, 1H), 3.80 (s, 6H), 3.51 (d, *J* = 17.6 Hz, 1H), 1.81 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.37, 175.80, 159.65, 157.06, 154.99, 146.59, 146.58, 135.30, 135.20, 132.13, 125.51, 125.47, 121.01, 120.87, 119.46, 119.23, 86.82, 46.68, 36.81, 22.99; HRMS (QFT-ESI) calcd for C₁₆H₁₃ClFN₄O₅S [M-H]⁻ 427.0285, found:427.0280.



3-(2,4-dichloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)phenyl)-5-methyl-4,5 -**dihydroisoxazole-5-carboxylic acid (6b).** White solid; m.p.: 95.1-96.9 °C; 81% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.71 (s, 1H), 7.64 (s, 1H), 4.00 (d, *J* = 17.6 Hz, 1H), 3.76 (s, 6H), 3.44 (d, *J* = 17.6 Hz, 1H), 1.75 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.51, 175.80, 154.84, 146.58, 135.19, 134.64, 132.16, 131.84, 130.84, 128.36, 86.96, 46.49, 36.77, 23.02; HRMS (QFT-ESI) calcd for C₁₆H₁₃Cl₂N₄O₅S [M-H]⁻ 442.9989, found: 442.9986.



3-(4-bromo-2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)phenyl)-5-meth yl-4,5-dihydroisoxazole-5-carboxylic acid (7b). White solid; m.p.: 113.9-115.9 °C; 67% yield; ¹H NMR (400 MHz, CDCl₃) 9.93 (s, 1H), 7.81 (s, 1H), 7.73 (s, 1H), 3.99 (d, J = 17.6 Hz, 1H), 3.76 (s, 6H), 3.52 (d, J = 7.0 Hz, 1H), 1.73 (s, 3H);; ¹³C NMR (101 MHz, CDCl₃) δ 177.52, 175.51, 154.91, 146.52, 146.50, 135.19, 134.65, 132.59, 131.66, 128.99, 125.10, 87.00, 46.47, 36.78, 23.04; HRMS (QFT-ESI) calcd for C₁₆H₁₃BrClN₄O₅S [M-H]⁻ 486.9479, found: 486.9482.



3-(2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)phenyl)-5-methyl-4,5-dih ydroisoxazole-5-carboxylic acid (8b). White solid; m.p.:117.5-119.5 °C; 78% yield; ¹H NMR (400 MHz, CDCl₃) δ 9.25 (s, 1H), 7.64 (d, J = 2.4 Hz, 1H), 7.54 (d, J = 8.4 Hz, 1H), 7.27 (d, J =4.4 Hz, 1H), 3.99 (d, J = 17.6 Hz, 1H), 3.74 (s, 6H), 3.48 (d, J = 17.6 Hz, 1H), 1.74 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.48, 175.77, 155.70, 147.36, 133.87, 132.75, 131.86, 130.86, 130.49, 129.50, 86.76, 46.74, 36.75, 23.03; HRMS (QFT-ESI) calcd for C₁₆H₁₄ClN₄O₅S [M-H]⁻ 409.0379, found: 409.0375.

5.6 Synthesis of compounds 5c-r, 6c-f, 7c-f and 8c-f.



General method to synthesize of compounds **5c-r**, **6c-f**, **7c-f** and **8c-f**. To a stirred mixture of **5b**, **6b**, **7b** or **8b** (2 mmol) in DMF (30 mL) was added K_2CO_3 (2.5 mmol) at room temperature. After 10 min, R⁴I or R⁴Br (1.25 mmol) was added to the mixture and then allowed to react for another 10 h. The reaction mixture was poured to water (150 mL), and extracted by ethyl acetate (60 mL).

The organic layer was washed with water (40 mL) and saturated NaCl solution (40 mL), dried over Na_2SO_4 . After removing the solvent in vacuum, the residue was purified by flash chromatography to give **5c-r**, **6c-e**, **7c-e** and **8c-e**.



methyl 3-(2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)-4-fluorophenyl) -5-methyl-4,5-dihydroisoxazole-5-carboxylate 5c. White solid; m.p.: 80.6-82.5 °C; 60% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.74 (d, J = 8.0 Hz, 1H), 7.36 (d, J = 9.2 Hz, 1H), 4.01 (d, J = 17.6 Hz, 1H), 3.82 (s, 3H), 3.77 (s, 6H), 3.41 (d, J = 17.2 Hz, 1H), 1.72 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.41, 172.09, 159.49, 156.91, 154.42, 146.55, 135.18, 135.08, 132.04, 125.87, 125.83, 120.96, 120.82, 119.40, 119.17, 87.22, 53.11, 46.58, 36.80, 23.38; HRMS (QFT-ESI) calcd for C₁₇H₁₆ClFN₄NaO₅S [M+Na]⁺465.0412, found: 465.0410.



propyl 3-(2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)-4-fluorophenyl) -5-methyl-4,5-dihydroisoxazole-5-carboxylate 5d. White solid; m.p.: 60.6-62.6 °C; 56% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.73 (d, J = 7.6 Hz, 1H), 7.36 (d, J = 8.8 Hz, 1H), 4.17 (t, J = 6.8 Hz, 2H), 4.01 (d, J = 17.2 Hz, 1H), 3.77 (s, 6H), 3.39 (d, J = 17.2 Hz, 1H), 1.80 – 1.64 (m, 5H), 0.96 (t, J = 7.6 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.56, 171.73, 159.64, 157.06, 154.48, 146.69, 135.37, 135.28, 132.19, 126.17, 126.13, 121.10, 120.97, 119.54, 119.31, 87.49, 67.78, 46.66, 36.96, 23.49, 22.03, 10.44; HRMS (QFT-ESI) calcd for C₁₉H₂₀ClFN₄NaO₅S [M+Na]⁺ 493.0725, found: 493.0725.



butyl 3-(2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)-4-fluorophenyl) -5-methyl-4,5-dihydroisoxazole-5-carboxylate 5e. White solid; m.p.:55.9-57.6 °C; 64% yield;

¹H NMR (400 MHz, CDCl₃) δ 7.78 (d, *J* = 7.6 Hz, 1H), 7.41 (d, *J* = 9.2 Hz, 1H), 4.25 (t, *J* = 6.8 Hz, 2H), 4.05 (d, *J* = 17.2 Hz, 1H), 3.81 (s, 6H), 3.43 (d, *J* = 17.2 Hz, 1H), 1.75 (s, 3H), 1.71 (dd, *J* = 14.8, 7.2Hz, 2H), 1.53 – 1.38 (m, 2H), 0.99 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.38, 171.58, 158.93, 156.25, 146.52, 135.19, 134.62, 132.02, 125.98, 120.84, 119.38, 119.23, 119.15, 87.31, 65.98, 46.48, 36.80, 30.48, 23.33, 19.04, 13.68; HRMS (QFT-ESI) calcd for C₂₀H₂₂ClFN₄NaO₅S [M+Na]⁺ 507.0881, found: 507.0881



Isopropyl 3-(2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)-4-fluorophenyl)-5-methyl-4,5-dihydroisoxazole-5-carboxylate 5f. White solid; m.p.: 62.5-64.1 °C; 79% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.73 (d, J = 8.0 Hz, 1H), 7.36 (d, J = 9.2 Hz, 1H), 5.09 (dt, J = 12.4, 6.0 Hz, 1H), 3.99 (d, J = 17.6 Hz, 1H), 3.77 (s, 6H), 3.37 (d, J = 17.2 Hz, 1H), 1.69 (s, 3H), 1.31 (s, 3H), 1.29 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.39, 171.00, 159.46, 156.88, 154.30, 146.55, 146.53, 135.24, 135.14, 132.03, 126.08, 126.04, 120.92, 120.78, 119.38, 119.15, 87.31, 69.89, 46.40, 36.81, 23.28, 21.64, 21.61; HRMS (QFT-ESI) calcd for C₁₉H₂₀ClFN₄NaO₅S [M+Na]⁺ 493.0725, found: 493.0723.



2-fluoroethyl 3-(2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)-4-fluoro phenyl)-5-methyl-4,5-dihydroisoxazole-5-carboxylate 5g. White solid; m.p.: 68.8-70.1 °C; 55% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.75 (d, J = 8.0 Hz, 1H), 7.38 (d, J = 9.2 Hz, 1H), 4.66 (dt, J = 47.2, 4.0 Hz, 2H), 4.47 (ddd, J = 28.0, 8.0, 3.6 Hz, 2H), 4.04 (d, J = 17.2 Hz, 1H), 3.78 (s, 6H), 3.52 – 3.36 (m, 1H), 1.76 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.41, 171.32, 159.54, 156.96, 154.43, 146.54, 135.25, 135.15, 132.08, 125.86, 125.82, 120.98, 120.84, 119.39, 119.17, 87.13, 81.71, 80.00, 64.79, 64.59, 46.57, 36.81, 36.78, 23.22.; HRMS (QFT-ESI) calcd for C₁₈H₁₇ClF₂N₄NaO₅S [M+Na]⁺497.0474, found: 497.0472.



2,2-difluoroethyl 3-(2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)-4-

fluorophenyl)-5-methyl-4,5-dihydroisoxazole-5-carboxylate 5h. White solid; m.p.: 66.5-68.5 °C; 65% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.71 (d, *J* = 7.6 Hz, 1H), 7.36 (d, *J* = 9.2 Hz, 1H), 5.99 (tt, *J* = 54.8, 4.0 Hz, 1H), 4.38 (tdd, *J* = 13.6, 4.0, 2.4 Hz, 2H), 4.00 (d, *J* = 17.6 Hz, 1H), 3.74 (s, 6H), 3.44 (d, *J* = 17.6 Hz, 1H), 1.73 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.46, 170.68, 159.59, 157.01, 154.53, 146.55, 135.17, 135.07, 132.09, 125.65, 125.61, 121.05, 120.92, 119.40, 119.17, 114.74, 112.34, 109.93, 86.95, 63.68, 63.39, 63.10, 46.55, 36.78, 36.75, 23.10; HRMS (QFT-ESI) calcd for C₁₈H₁₆ClF₃N₄NaO₅S [M+Na]⁺ 515.0380, found: 515.0378.



3-fluoropropyl 3-(2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)-4fluorophenyl)-5-methyl-4,5-dihydroisoxazole-5-carboxylate 5i. White solid; m.p.: 62.1-63.4 °C; 67% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.71 (d, *J* = 7.6 Hz, 1H), 7.36 (d, *J* = 8.8 Hz, 1H), 4.53 (dt, *J* = 47.2, 5.2 Hz, 2H), 4.32 (t, *J* = 6.0 Hz, 2H), 3.99 (d, *J* = 17.6 Hz, 1H), 3.73 (s, 6H), 3.39 (d, *J* = 17.6 Hz, 1H), 2.16 – 1.97 (m, 2H), 1.69 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.48, 171.36, 159.48, 156.90, 154.48, 146.54, 135.09, 134.99, 132.04, 125.80, 121.00, 120.86, 119.36, 119.13, 87.17, 81.27, 79.63, 62.11, 62.06, 46.44, 36.75, 29.64, 29.44, 23.19; HRMS (QFT-ESI) calcd for C₁₉H₁₉ClF₂N₄NaO₅S [M+Na]⁺ 511.0630, found: 511.0630.



2-ethoxy-2-oxoethyl 3-(2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl) -4-fluorophenyl)-5-methyl-4,5-dihydroisoxazole-5-carboxylate 5j. White solid; m.p.: 56.3-58.2 °C; 87% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.75 (d, J = 7.6 Hz, 1H), 7.37 (d, J = 8.8 Hz, 1H), 4.72 (s, 2H), 4.22 (q, J = 7.2 Hz, 2H), 4.11 (d, J = 18.0 Hz, 1H), 3.76 (s, 6H), 3.47 (d, J= 17.6 Hz, 1H), 1.78 (s, 3H), 1.27 (t, J = 7.2 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.43, 171.13, 167.10, 159.51, 156.93, 154.44, 146.53, 135.21, 135.12, 132.09, 125.80, 125.76, 120.95, 120.82, 119.39, 119.16, 86.97, 61.68, 61.48, 46.77, 36.79, 23.12, 14.09; HRMS (QFT-ESI) calcd for C₂₀H₂₀ClFN₄NaO₇S [M+Na]⁺ 537.0623, found: 537.0620.



1-ethoxy-1-oxopropan-2-yl 3-(2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan -1-yl)-4-fluorophenyl)-5-methyl-4,5-dihydroisoxazole-5-carboxylate 5k. White solid; m.p.: 116.2-118.2 °C; 53% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.74 (dd, J = 7.6, 4.8 Hz, 1H), 7.36 (dd, J = 9.2, 2.4 Hz, 1H), 5.15 (q, J = 7.2 Hz, 1H), 4.20 (qd, J = 7.2, 3.6 Hz, 2H), 4.11 (d, J = 17.2 Hz, 1H), 3.77 (s, 6H), 3.45 (d, J = 17.2 Hz, 1H), 1.77 (d, J = 17.6 Hz, 3H), 1.56 (t, J = 7.2 Hz, 3H), 1.26 (td, J = 7.2, 2.4 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.48, 171.03, 170.95, 170.12, 159.51, 156.93, 154.58, 154.23, 146.57, 146.55, 135.22, 135.12, 132.14, 132.09, 125.91, 125.87, 120.98, 120.84, 119.39, 119.16, 87.14, 86.79, 69.86, 69.82, 61.63, 47.01, 46.30, 36.80, 23.22, 22.98, 16.77, 16.74, 14.12; HRMS (QFT-ESI) calcd for C₂₁H₂₂ClFN₄NaO₇S [M+Na]⁺ 551.0779, found: 551.0778.



1-ethoxy-2-methyl-1-oxopropan-2-yl 3-(2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo -1,3,5-triazinan-1-yl)-4-fluorophenyl)-5-methyl-4,5-dihydroisoxazole-5-carboxylate 5l. White solid; m.p.: 57.9-59.8 °C; 55% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.73 (d, J = 7.6 Hz, 1H), 7.36 (d, J = 9.2 Hz, 1H), 4.18 (q, J = 7.2 Hz, 2H), 4.03 (d, J = 17.6 Hz, 1H), 3.77 (s, 6H), 3.38 (d, J = 17.6 Hz, 1H), 1.72 (s, 3H), 1.61 (d, J = 4.8 Hz, 6H), 1.23 (t, J = 7.2 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.41, 171.88, 170.31, 159.48, 156.90, 154.24, 146.55, 146.50, 135.21, 135.11, 132.03, 125.96, 125.92, 120.96, 120.82, 119.38, 119.14, 87.09, 79.98, 61.51, 46.47, 36.79, 24.57, 24.42, 23.03, 14.04; HRMS (QFT-ESI) calcd for C₂₂H₂₄ClFN₄NaO₇S [M+Na]⁺ 565.0936, found: 565.0935.



2-ethoxy-1-fluoro-2-oxoethyl 3-(2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-

triazinan-1-yl)-4-fluorophenyl)-5-methyl-4,5-dihydroisoxazole-5-carboxylate 5m. White solid; m.p.: 50.2-52.1 °C; 55% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.74 (d, J = 7.6 Hz, 1H), 7.37 (d, J = 9.2 Hz, 1H), 6.46 (d, J = 52.4 Hz, 1H), 4.34 (q, J = 7.2 Hz, 2H), 4.04 (dd, J = 17.6, 5.2 Hz, 1H), 3.77 (s, 6H), 3.49 (d, J = 17.6 Hz, 1H), 1.79 (s, 3H), 1.33 (t, J = 7.2 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.38, 169.02, 163.48, 159.67, 157.08, 154.39, 146.55, 146.50, 135.27, 135.18, 132.14, 125.50, 121.06, 120.92, 119.45, 119.22, 96.82, 94.47, 86.64, 63.03, 46.54, 36.81, 22.84, 13.95; HRMS (QFT-ESI) calcd for C₂₀H₁₉ClF₂N₄NaO₇S [M+Na]⁺ 555.0529, found: 555.0527.



2-ethoxy-1,1-difluoro-2-oxoethyl 3-(2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-

1,3,5-triazinan-1-yl)-4-fluorophenyl)-5-methyl-4,5-dihydroisoxazole-5-carboxylate 5n. White solid; m.p.: 62.0-64.0 °C; 25% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.66 (d, *J* = 7.6 Hz, 1H), 7.28 (d, *J* = 9.2 Hz, 1H), 4.20 (tt, *J* = 13.6, 6.8 Hz, 2H), 3.92 (d, *J* = 17.6 Hz, 1H), 3.68 (s, 6H), 3.32 (d, *J* = 17.6 Hz, 1H), 1.62 (s, 3H), 1.24 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 176.42, 170.50, 166.66, 158.45, 155.87, 153.34, 145.52, 134.15, 134.05, 131.30, 131.02, 129.89, 127.82, 124.95, 124.92, 119.95, 119.82, 118.34, 118.10, 86.21, 61.12, 45.47, 35.75, 22.29, 13.07, 12.71; HRMS (QFT-ESI) calcd for C₂₀H₁₈ClF₃N₄NaO₇S [M+Na]⁺ 573.0435, found: 573.0433.



benzyl 3-(2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)-4-fluorophenyl) -5-methyl-4,5-dihydroisoxazole-5-carboxylate 50. White solid; m.p.: 173.8-175.8 °C; 75% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.69 (d, J = 7.6 Hz, 1H), 7.43 – 7.31 (m, 6H), 5.23 (d, J = 0.8 Hz, 2H), 3.98 (d, J = 17.2 Hz, 1H), 3.77 (s, 6H), 3.39 (d, J = 17.2 Hz, 1H), 1.72 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.38, 171.29, 159.49, 156.91, 154.38, 146.52, 146.49, 135.25, 135.19, 135.15, 132.03, 128.64, 128.45, 128.18, 128.16, 128.15, 125.93, 125.89, 120.92, 120.78, 119.36, 119.13, 87.26, 67.59, 46.55, 36.79, 23.20; HRMS (QFT-ESI) calcd for C₂₃H₂₀ClFN₄NaO₅S [M+Na]⁺ 541.0725, found: 541.0724.



4-(trifluoromethyl)benzyl 3-(2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)-4-fluorophenyl)-5-methyl-4,5-dihydroisoxazole-5-carboxylate 5p. White solid; m.p.: 158.8-159.9 °C; 94% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.72 (d, J = 7.6 Hz, 1H), 7.63 (d, J = 8.4 Hz, 2H), 7.48 (d, J = 8.0 Hz, 2H), 7.36 (d, J = 9.2 Hz, 1H), 5.29 (s, 2H), 4.01 (d, J = 17.6 Hz, 1H), 3.77 (s, 6H), 3.42 (d, J = 17.6 Hz, 1H), 1.74 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.50, 171.15, 162.50, 159.54, 156.96, 154.53, 146.57, 139.25, 135.07, 134.98, 132.05, 128.02, 125.63, 125.60, 121.10, 120.96, 119.36, 119.13, 87.17, 66.46, 46.52, 36.70, 23.07; HRMS (QFT-ESI) calcd for C₂₄H₁₉ClFN₄NaO₅S [M+Na]⁺ 609.0599, found: 609.0598.



4-fluorobenzyl 3-(2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)-4fluorophenyl)-5-methyl-4,5-dihydroisoxazole-5-carboxylate 5q. White solid; m.p.: 141.8-143.8 °C; 75% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.68 (d, J = 7.6 Hz, 1H), 7.35 (dt, J = 5.2, 2.4 Hz, 3H), 7.04 (t, J = 8.8 Hz, 2H), 5.20 (s, 2H), 3.96 (d, J = 17.6 Hz, 1H), 3.77 (d, J = 1.6 Hz, 6H), 3.61 – 3.30 (m, 1H), 1.71 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.40, 171.30, 163.99, 161.53, 159.51, 156.93, 154.45, 146.54, 135.21, 135.11, 132.02, 131.08, 131.04, 130.33, 130.24, 125.86, 125.81, 120.97, 120.83, 119.38, 119.15, 115.73, 115.51, 87.22, 66.88, 46.53, 36.80, 23.14; HRMS (QFT-ESI) calcd for C₂₃H₁₉ClF₂N₄NaO₅S [M+Na]⁺ 559.0630, found: 559.0630.



4-methylbenzyl 3-(2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)-4fluorophenyl)-5-methyl-4,5-dihydroisoxazole-5-carboxylate 5r. White solid; m.p.: 167.1-168.6 °C; 61% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.71 (d, J = 7.6 Hz, 1H), 7.34 (d, J = 9.2 Hz, 1H), 7.25 (d, J = 8.0 Hz, 2H), 7.16 (d, J = 8.0 Hz, 2H), 5.19 (d, J = 1.2 Hz, 2H), 3.97 (d, J = 17.2 Hz, 1H), 3.76 (d, J = 1.2 Hz, 6H), 3.37 (d, J = 17.6 Hz, 1H), 2.34 (s, 3H), 1.70 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.46, 171.28, 159.49, 156.91, 154.36, 146.56, 146.53, 138.34, 135.19, 135.10, 132.25, 132.07, 129.32, 129.19, 128.32, 127.05, 125.96, 125.92, 120.99, 120.85, 119.34, 119.11, 87.26, 67.58, 46.53, 36.80, 36.77, 23.24, 21.24; HRMS (QFT-ESI) calcd for C₂₄H₂₂ClFN₄NaO₅S [M+Na]⁺ 555.0881, found: 555.0882.



methyl 3-(2,4-dichloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)phenyl)-5methyl -4,5-dihydroisoxazole-5-carboxylate 6c. White solid; m.p.: 76.4-78.4 °C; 63% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.69 (s, 1H), 7.58 (s, 1H), 3.94 (d, J = 17.6 Hz, 1H), 3.74 (s, 3H), 3.70 (s, 6H), 3.34 (d, J = 17.6 Hz, 1H), 1.64 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.53, 171.99, 154.34, 146.49, 134.94, 134.57, 132.15, 131.73, 130.81, 128.67, 87.36, 53.08, 46.45, 36.74, 23.37; HRMS (QFT-ESI) calcd for C₁₇H₁₆Cl₂N₄NaO₅S [M+Na]⁺ 481.0116, found: 481.0115.



propyl 3-(2,4-dichloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)phenyl)-5methyl -4,5-dihydroisoxazole-5-carboxylate 6d. White solid; m.p.: 55.5-57.2 °C; 67% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.73 (s, 1H), 7.63 (s, 1H), 4.15 (t, *J* = 6.4 Hz, 2H), 4.00 (d, *J* = 17.2 Hz, 1H), 3.76 (s, 6H), 3.37 (d, *J* = 17.6 Hz, 1H), 1.75 – 1.64 (m, 5H), 0.94 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.57, 171.44, 154.31, 146.50, 134.86, 134.53, 132.09, 131.75, 130.83, 128.76, 87.43, 67.59, 46.32, 36.71, 23.30, 21.86, 10.29; HRMS (QFT-ESI) calcd for C₁₉H₂₀Cl₂N₄NaO₅S [M+Na]⁺ 509.0429, found: 509.0428.



butyl 3-(2,4-dichloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)phenyl)-5-

methyl-4,5-dihydroisoxazole-5-carboxylate 6e. White solid; m.p.: 52.7-54.6 °C; 67% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.75 (s, 1H), 7.65 (s, 1H), 4.21 (t, J = 6.4 Hz, 2H), 4.01 (d, J = 17.6 Hz, 1H), 3.78 (s, 6H), 3.39 (d, J = 17.2 Hz, 1H), 1.76 – 1.62 (m, 5H), 1.40 (dq, J = 14.8, 7.2 Hz, 2H), 0.94 (t, J = 7.2 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.55, 171.46, 154.29, 146.49, 134.87, 134.56, 132.11, 131.74, 130.81, 128.77, 87.44, 65.96, 46.33, 36.73, 30.48, 23.31, 19.03, 13.67; HRMS (QFT-ESI) calcd for C₂₀H₂₂Cl₂N₄NaO₅S [M+Na]⁺ 523.0586, found: 523.0584.



methyl 3-(4-bromo-2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)phenyl) -5-methyl-4,5-dihydroisoxazole-5-carboxylate 7c. White solid; m.p.: 86.5-88.4 °C; 94% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.81 (s, 1H), 7.75 (s, 1H), 4.02 (d, J = 17.6 Hz, 1H), 3.82 (s, 3H), 3.78 (s, 6H), 3.42 (d, J = 17.6 Hz, 1H), 1.72 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.56, 171.96, 154.46, 146.46, 135.13, 134.52, 132.59, 131.57, 129.26, 124.83, 87.36, 53.10, 46.38, 36.74, 23.36; HRMS (QFT-ESI) calcd for C₁₇H₁₇BrClN₄O₅S [M+H]⁺ 502.9792, found: 502.9790.



propyl 3-(4-bromo-2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)

phenyl)-5-methyl-4,5-dihydroisoxazole-5-carboxylate 7d. White solid; m.p.: 61.7-63.2 °C; 91% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.83 (s, 1H), 7.76 (s, 1H), 4.19 (t, J = 6.8 Hz, 2H), 4.04 (d, J = 17.2 Hz, 1H), 3.80 (s, 6H), 3.42 (d, J = 17.6 Hz, 1H), 1.81 – 1.67 (m, 5H), 0.98 (t, J = 7.2Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.56, 171.44, 154.40, 146.46, 146.44, 135.10, 134.52, 132.58, 131.58, 129.36, 124.77, 87.46, 67.60, 46.27, 36.73, 23.32, 21.87, 10.31; HRMS (QFT-ESI) calcd for C₁₉H₂₀BrClN₄NaO₅S [M+H]⁺ 552.9924, found: 552.9923.



butyl 3-(4-bromo-2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)phenyl)

-5-methyl-4,5-dihydroisoxazole-5-carboxylate 7e. White solid; m.p.: 58.2-60.0 °C; 95% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.81 (s, 1H), 7.74 (s, 1H), 4.21 (t, *J* = 6.4 Hz, 2H), 4.01 (d, *J* = 17.2 Hz, 1H), 3.78 (s, 6H), 3.39 (d, *J* = 17.2 Hz, 1H), 1.71 (s, 3H), 1.66 (dd, *J* = 14.8, 6.8 Hz, 2H), 1.40 (dq, *J* = 15.2, 7.6 Hz, 2H), 0.94 (t, *J* = 7.6 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.58, 171.39, 154.41, 146.46, 146.43, 135.05, 134.46, 132.61, 131.59, 129.34, 124.75, 87.42, 65.91, 46.23, 36.70, 30.46, 23.28, 19.04, 13.71; HRMS (QFT-ESI) calcd for C₂₀H₂₃BrClN₄O₅S [M+H]⁺ 545.0261, found: 545.0260.



methyl 3-(2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)phenyl)-5-methyl -4,5-dihydroisoxazole-5-carboxylate 8c. White solid; m.p.: 86.6-88.4 °C; 78% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.67 (d, J = 2.8 Hz, 1H), 7.55 (d, J = 8.8 Hz, 1H), 7.30 – 7.26 (m, 1H), 4.02 (d, J = 17.6 Hz, 1H), 3.81 (s, 3H), 3.76 (s, 6H), 3.44 (d, J = 17.6 Hz, 1H), 1.72 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.46, 172.17, 155.11, 147.25, 133.82, 132.69, 131.85, 130.62, 130.40, 129.82, 87.14, 53.07, 46.67, 36.72, 23.39; HRMS (QFT-ESI) calcd for C₁₇H₁₇ClN₄NaO₅S [M+Na]⁺ 447.0506, found: 447.0504.



propyl 3-(2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)phenyl)-5-methyl -**4,5-dihydroisoxazole-5-carboxylate 8d**. White solid; m.p.: 64.1-65.9 °C; 85% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.66 (d, J = 2.4 Hz, 1H), 7.55 (d, J = 8.4 Hz, 1H), 7.26 (dd, J = 8.4, 2.4 Hz, 1H), 4.17 (t, J = 6.8 Hz, 2H), 4.03 (d, J = 17.6 Hz, 1H), 3.76 (s, 6H), 3.42 (d, J = 17.6 Hz, 1H), 1.82 – 1.67 (m, 5H), 0.96 (t, J = 7.6 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.47, 171.69, 155.07, 147.26, 133.87, 132.68, 131.84, 130.58, 130.42, 129.97, 87.26, 67.60, 46.59, 36.74, 23.37, 21.88, 10.31; HRMS (QFT-ESI) calcd for C₁₉H₂₁ClN₄NaO₅S [M+Na]⁺ 475.0819, found: 475.0818.



butyl 3-(2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)phenyl)-5-methyl -4,5-dihydroisoxazole-5-carboxylate 8e. White solid; m.p.: 61.2-63.0 °C; 85% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.66 (d, J = 2.4 Hz, 1H), 7.55 (d, J = 8.8 Hz, 1H), 7.26 (dd, J = 8.4, 2.4 Hz, 1H), 4.21 (t, J = 6.4 Hz, 2H), 4.02 (d, J = 17.2 Hz, 1H), 3.76 (s, 6H), 3.42 (d, J = 17.6 Hz, 1H), 1.71 (s, 3H), 1.70 – 1.59 (m, 2H), 1.49 – 1.31 (m, 2H), 0.94 (t, J = 7.2 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.47, 171.69, 155.05, 147.26, 133.87, 132.68, 131.84, 130.58, 130.42, 129.97, 87.24, 77.37, 77.25, 77.05, 76.74, 65.96, 46.59, 36.74, 30.49, 23.37, 19.05, 13.70; HRMS (QFT-ESI) calcd for C₂₀H₂₃ClN₄NaO₅S [M+Na]⁺489.0975, found: 489.0975.

5.7 Synthesis of compounds 9.



General method to synthesize of compounds **9**. Compound **5b**, **6b**, **7b**, or **8b** (1 mmol) was dissolved in CH₂Cl (20 mL) and cooled to 0 °C, (COCl)₂ (1.25 mmol) was added dropwise to the solution. Then the reaction solution was stirred at 0 °C for 1 h, and moved to the room temperature for another 2 hours. After removing the solvent by rotary evaporation, CH₂Cl (30 mL) was added to the flask to dissolve the residue, and the resulting solution was cooled to 0 °C, R^5NH_2 (1.05 mmol) was added to the solution. The reaction solution was stirred for 30 min at 0 °C, and then moved to room temperature for another 3 hours. After completing the reaction, H₂O (20 mL) was added to the solution, the organic layer was separated and washed with water (40 mL) and saturated NaCl solution (40 mL), dried over Na₂SO₄. After removing the solvent in vacuum, the residue was purified by flash chromatography to give compounds **9**.



3-(2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)-4-fluorophenyl)-N,5-di methyl-4,5-dihydroisoxazole-5-carboxamide 9a. White solid; m.p.: 102.0-104.0 °C; 81% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.66 (d, J = 7.6 Hz, 1H), 7.37 (d, J = 9.2 Hz, 1H), 6.84 (d, J = 4.8 Hz, 1H), 3.97 (d, J = 17.6 Hz, 1H), 3.76 (s, 6H), 3.38 (d, J = 17.6 Hz, 1H), 2.83 (d, J = 5.2 Hz, 3H), 1.71 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.37, 173.51, 159.51, 156.93, 155.92, 146.57, 135.43, 135.33, 131.81, 125.65, 125.61, 120.88, 120.74, 119.60, 119.37, 88.52, 47.15, 36.81, 26.12, 23.83; HRMS (QFT-ESI) calcd for C₁₇H₁₇CIFN₅NaO₄S [M+Na]⁺ 464.0572, found: 464.0570.



3-(2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)-4-fluorophenyl)-N-ethyl -**5-methyl-4,5-dihydroisoxazole-5-carboxamide 9b**. White solid; m.p.: 97.9-99.9 °C; 69% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.68 (d, J = 7.6 Hz, 1H), 7.39 (d, J = 9.2 Hz, 1H), 6.80 (s, 1H), 3.99 (d, J = 17.6 Hz, 1H), 3.79 (s, 6H), 3.39 (d, J = 17.6 Hz, 1H), 3.31 (dd, J = 14.0, 6.8 Hz, 2H), 1.73 (s, 3H), 1.18 (t, J = 7.2 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.39, 172.68, 159.52, 156.94, 155.90, 146.55, 135.47, 135.37, 131.81, 125.73, 125.69, 120.90, 120.76, 119.59, 119.36, 88.44, 65.84, 47.13, 36.80, 34.31, 23.81, 14.67; HRMS (QFT-ESI) calcd for C₁₈H₁₉ClFN₅NaO₄S [M+Na]⁺478.0728, found: 478.0726.



3-(2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)-4-fluorophenyl)-5-meth yl-N-propyl-4,5-dihydroisoxazole-5-carboxamide 9c. White solid; m.p.: 85.0-87.0 °C; 81% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.65 (d, J = 7.6 Hz, 1H), 7.37 (d, J = 8.8 Hz, 1H), 6.81 (t, J = 5.6 Hz, 1H), 3.97 (d, J = 18.0 Hz, 1H), 3.77 (s, 6H), 3.36 (d, J = 17.6 Hz, 1H), 3.32 – 3.14 (m, 2H), 1.71 (s, 3H), 1.54 (h, J = 7.2 Hz, 2H), 0.92 (t, J = 7.2 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.38, 172.82, 159.52, 156.94, 155.96, 146.54, 135.48, 135.38, 131.80, 125.73, 125.69, 120.89, 120.75, 119.58, 119.35, 88.50, 47.13, 41.03, 36.80, 23.82, 22.69, 11.26; HRMS (QFT-ESI) calcd for C₁₉H₂₁ClFN₅NaO₄S [M+Na]⁺492.0885, found: 492.0883.



3-(2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)-4-fluorophenyl)-N-isopr opyl-5-methyl-4,5-dihydroisoxazole-5-carboxamide 9d. White solid; m.p.: 87.9-89.9 °C; 77% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.65 (d, J = 7.2 Hz, 1H), 7.38 (d, J = 8.4 Hz, 1H), 6.62 (d, J = 7.6 Hz, 1H), 4.04 (dd, J = 13.2, 6.8 Hz, 1H), 3.96 (d, J = 17.2 Hz, 1H), 3.77 (s, 6H), 3.45 – 3.30 (m, 1H), 1.70 (s, 3H), 1.17 (dd, J = 14.0, 6.4 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 177.34, 171.88, 159.49, 156.91, 155.90, 146.55, 146.50, 135.50, 135.40, 131.75, 125.74, 125.70, 120.85, 120.71, 119.58, 119.35, 88.36, 47.05, 41.42, 36.81, 23.77, 22.62, 22.55. 3H), 1.17 (dd, J = 14.1, 6.4 Hz, 6H); HRMS (QFT-ESI) calcd for C₁₉H₂₁ClFN₅NaO₄S [M+Na]⁺ 492.0885, found: 492.0885.



N-butyl-3-(2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)-4-fluorophenyl) -5-methyl-4,5-dihydroisoxazole-5-carboxamide 9e. White solid; m.p.: 72.0-74.0 °C; 83% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.65 (d, J = 7.6 Hz, 1H), 7.37 (d, J = 9.2 Hz, 1H), 6.79 (t, J = 5.6 Hz, 1H), 3.97 (d, J = 18.0 Hz, 1H), 3.77 (s, 6H), 3.36 (d, J = 17.6 Hz, 1H), 3.26 (qd, J = 13.2, 6.0 Hz, 2H), 1.71 (s, 3H), 1.56 – 1.46 (m, 2H), 1.34 (dd, J = 15.2, 7.6 Hz, 2H), 0.92 (t, J = 7.6 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.36, 172.77, 159.52, 156.94, 155.97, 146.54, 146.53, 135.49, 135.39, 131.80, 125.73, 125.69, 120.87, 120.74, 119.59, 119.36, 88.50, 47.12, 39.11, 36.81, 31.47, 23.81, 19.99, 13.71; HRMS (QFT-ESI) calcd for C₂₀H₂₃ClFN₅NaO₄S [M+Na]⁺ 506.1041, found: 506.1039.



3-(2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)-4-fluorophenyl)-N-isobu tyl-5-methyl-4,5-dihydroisoxazole-5-carboxamide 9f. White solid; m.p.: 86.3-88.2 °C; 85% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.64 (d, J = 7.6 Hz, 1H), 7.37 (d, J = 8.8 Hz, 1H), 6.86 (t, J = 6.0 Hz, 1H), 3.98 (d, J = 18.0 Hz, 1H), 3.77 (s, 6H), 3.36 (d, J = 18.0 Hz, 1H), 3.18 – 3.01 (m, 2H), 1.80 (td, J = 13.2, 6.8 Hz, 1H), 1.72 (s, 3H), 0.94 – 0.87 (m, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 177.36, 172.88, 159.53, 156.94, 156.07, 146.55, 146.51, 135.51, 135.41, 131.81, 125.72, 125.68, 120.87, 120.73, 119.60, 119.37, 88.55, 47.11, 46.56, 36.82, 28.48, 23.82, 20.02, 19.99; HRMS (QFT-ESI) calcd for C₂₀H₂₃ClFN₅NaO₄S [M+Na]⁺ 506.1041, found: 506.1038.



N-(tert-butyl)-3-(2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)-4-fluorop henyl)-5-methyl-4,5-dihydroisoxazole-5-carboxamide 9g. White solid; m.p.: 94.3-95.8 °C; 82% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.65 (d, J = 7.6 Hz, 1H), 7.38 (d, J = 8.8 Hz, 1H), 6.62 (s, 1H), 3.96 (d, J = 18.0 Hz, 1H), 3.77 (s, 6H), 3.31 (d, J = 17.6 Hz, 1H), 1.68 (s, 3H), 1.36 (s, 9H); ¹³C NMR (101 MHz, CDCl₃) δ 177.34, 171.97, 159.48, 156.90, 155.88, 146.55, 146.49, 135.53, 135.43, 131.74, 125.81, 125.77, 120.83, 120.70, 119.56, 119.33, 88.52, 51.13, 46.95, 36.80, 28.58, 23.77; HRMS (QFT-ESI) calcd for C₂₀H₂₃ClFN₅NaO₄S [M+Na]⁺ 506.1041, found: 506.1040.



N-benzyl-3-(2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)-4-fluoropheny I)-5-methyl-4,5-dihydroisoxazole-5-carboxamide 9h. White solid; m.p.: 96.0-98 °C; 86% yield; ¹H NMR (400 MHz, CDCl₃) δ 7.62 (d, J = 7.6 Hz, 1H), 7.37 (d, J = 8.8 Hz, 1H), 7.31 (dd, J = 14.4, 6.8 Hz, 3H), 7.24 (d, J = 8.0 Hz, 2H), 7.13 (t, J = 5.2 Hz, 1H), 4.45 (qd, J = 14.8, 6.0 Hz, 2H), 4.01 (d, J = 17.6 Hz, 1H), 3.77 (d, J = 3.2 Hz, 6H), 3.40 (d, J = 18.0 Hz, 1H), 1.75 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 177.40, 172.88, 159.56, 156.98, 156.07, 146.53, 137.70, 135.44, 135.34, 131.82, 128.75, 127.61, 127.55, 125.68, 125.64, 120.92, 120.79, 119.56, 119.33, 88.53, 47.16, 43.32, 36.79, 23.73; HRMS (QFT-ESI) calcd for C₂₃H₂₁ClFN₅NaO₄S [M+Na]⁺ 540.0885, found: 540.0884.



3-(2-chloro-5-(3,5-dimethyl-2,6-dioxo-4-thioxo-1,3,5-triazinan-1-yl)-4-fluorophenyl)-N-(N-is opropyl-N-methylsulfamoyl)-5-methyl-4,5-dihydroisoxazole-5-carboxamide 9i. White solid; m.p.: 87.6-88.9 °C; 81% yield; ¹H NMR (400 MHz, CDCl₃) δ 9.05 (s, 1H), 7.70 (d, J = 7.6 Hz, 1H), 7.37 (d, J = 8.8 Hz, 1H), 4.18 (dt, J = 13.6, 6.8 Hz, 1H), 4.00 (d, J = 18.0 Hz, 1H), 3.77 (s, 6H), 3.41 (d, J = 17.6 Hz, 1H), 2.88 (s, 3H), 1.73 (s, 3H), 1.18 – 1.09 (m, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 177.38, 171.72, 159.84, 157.25, 156.25, 146.58, 146.48, 135.38, 135.28, 132.09, 125.06, 125.02, 121.14, 121.00, 119.61, 119.38, 88.26, 49.80, 46.76, 36.81, 28.58, 23.13, 19.92, 19.84, 19.78; HRMS (QFT-ESI) calcd for C₂₀H₂₄ClFN₆NaO₆S₂ [M+Na]⁺ 585.0769, found: 585.0768.

Representative ¹H NMR and ¹³C NMR Spectrum.

7.745 7.726 7.373 7.351	4.293 4.255 4.257 4.027 4.027 3.383 3.378 3.370	-1.709 -1.342 -1.324 -1.306
Y Y		$ \checkmark$



























4.734 4.724 4.724 4.616 4.616 4.616 4.616 4.616 4.430 4.430 4.436 4.446 4.446 4.44164.4416 4.44164.4416 4.4416 4.4416 4.4416 4.44164.4416 4.4416 4.44164.4416 4.4416 4.44164.4416 4.4416 4.44164.4416 4.4416 4.44164.4416 4.4416 4.44164.4416 4.4416 4.44164.4416 4.44164.4416 4.4416 4.44164.4416 4.44164.4416 4.44164.4416 4.44164.4416 4.44164.4416 4.44164.4416 4.44164.4416 4.44164.4416 4.44164.4416 4.44164.4416 4.44164.4416 4.44164.44164



7.7.719
7.7.770
7.7.770
7.7.770
7.7.770
7.7.770
7.7.770
7.7.770
7.7.735
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.119
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144
6.144



7.761 7.742 7.376 -4.718 -4.247 -4.229 -4.211 -4.124 -4.127 -4.127 -4.083 -3.488 -3.444 -3.444 -1.783 $\begin{pmatrix} 1.292\\ 1.274\\ 1.257 \end{pmatrix}$ 5j 6.0 5.5 5.0 4.5 4.0 3.5 f1 (ppm) 1.00⊣ 0.96-≖ 3.09-1 3.30H 7.5 3.0 2.5 2.0 1.5 9.5 9.0 8.5 8.0 7.0 6.5 1.0 0.5 0.0 -0.5 -1.1 ~159.507 -156.926 ~154.441 -146.533 -146.533 -135.117 -135.094 -135.757 -125.757 -120.955 -120.918 -119.388 -119.158~177.429 ~171.128 ~167.098 -86,968 -46.766 61.683
61.481 -36.786 -23.124 0 5j 120 110 100 90 80 f1 (ppm) 190 180 170 160 150 140 130 70 60 50 40 30 20 10 0 -10 -2

7.7760 7.7741 7.773 7.7351 7.3556 7.3579 7.3556 7.3556 7.3556 7.3556 7.3556 7.3556 7.3556 7.3556 7.3556 7.3556 5.1755 5.1755 5.1755 5.1755 5.1755 5.1755 5.1755 5.17555.















~7.728



















7.257 7.257 7.278 7.278 7.278 7.278 7.272 7.257

$\begin{array}{c} 4.185\\ 4.168\\ 4.151\\ 4.151\\ 4.050\\ 3.343\\ 3.343\\ 3.343\\ 3.343\\ 3.399\\ 1.776\\ 1.776\\ 1.776\\ 1.776\\ 1.776\\ 1.776\\ 1.776\\ 0.963\\ 0.944\end{array}$









 $\zeta_{7,654}^{7,654}$ $\zeta_{7,355}^{7,365}$ $\zeta_{7,365}^{7,365}$ $\zeta_{6,609}^{6,609}$ $\zeta_{6,609}^{6,609}$ $\zeta_{6,609}^{1,365}$ $\zeta_{6,609}^{1,369}$ $\zeta_{6,609}^{1,106}$ $\zeta_{6,609}^{1,109}$ $\zeta_{6,609}^{1,109}$ $\zeta_{6,609}^{1,109}$



 $\begin{array}{c} 7.654 \\ 7.634 \\ 7.361 \\ 6.877 \\ 6.857 \\ 6.843 \\ 6.843 \end{array}$

-4,007 -3,562 -3,768 -3,568 -3,338 -3



 $\zeta_{7,657}^{7,657}$ $\zeta_{7,366}^{7,366}$ -6.619-6.619-3.385 $\zeta_{3,385}^{3,3985}$ $\zeta_{3,385}^{3,3985}$ $\zeta_{3,284}^{3,3985}$ $\zeta_{3,284}^{3,3284}$ $\zeta_{3,284}^{3,3284}$

